NJ Judge Not Convinced Epidiolex Seller Lied To USPTO

By Dani Kass · January 11, 2024, 10:48 PM EST

A New Jersey federal judge on Thursday dismissed allegations that 19 Jazz Pharmaceuticals patents covering its epilepsy treatment Epidiolex aren't enforceable, saying there's no evidence that the company lied to the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. TEVA PHARMACEUTICALS, INC. et al

Case Number

Court

New Jersey

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

January 03, 2023

Recent Articles By Dani

May 28, 2024
Edwards Urges Full Fed. Circ. To Limit FDA Safe Harbor
April 05, 2024
Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor
February 20, 2024
Fed. Circ. Backs Microsoft's PTAB Win Over 3D Patents
February 08, 2024
HHS Won't Invoke IP Rights To Lessen Xtandi Prices
January 30, 2024
CDC Patent Apps Lead Gilead To Victory In HIV Research Feud
December 13, 2023
The Biggest Patent Rulings Of 2023
November 17, 2023
FDA's Lack Of Power May Limit FTC's Patent Challenge
November 02, 2023
Nonprofit Calls For CMS-Amgen Price Talks To Reflect Abuse
October 24, 2023
AliveCor Urges Stay In Calif. While Challenging Apple Patents
August 08, 2023
Fed. Circ. Told Apple Watch Ban Could Turn ITC 'Meaningless'